ASHA-091

ASHA-091 is a novel mitochondrial dynamics targeting drug developed by Asha Therapeutics designed to inhibit mitochondrial fragmentation by specifically inhibiting DRP1 activation, a regulatory protein involved in mitochondrial fragmentation. This inhibition restores normal mitochondrial function and has demonstrated disease-modifying efficacy as a functional cure in preclinical models of neurodegenerative diseases such as Parkinson’s Disease and Alzheimer’s Disease. It also shows promise for treating other conditions linked to mitochondrial dysfunction including ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome), Long COVID, Amyotrophic Lateral Sclerosis (ALS), stroke, and post-viral fatigue syndromes. The drug acts as a degradable molecular glue with mechanisms involving DENR inhibitors (density regulated re-initiation and release factor inhibitors) and UTRN modulators (Utrophin modulators). Preclinical studies have shown robust efficacy in reversing motor impairment in Parkinson’s disease mouse models and improving activity levels in ME/CFS models. Clinical trials are planned to begin by late 2024[1][2][3][4][5][7].

Other names

ASHA-091ASHA091ASHA 091